Ken Kobayashi - 29 Dec 2023 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Medical Officer
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Ken Kobayashi
Issuer symbol
PYXS
Transactions as of
29 Dec 2023
Net transactions value
$0
Form type
4
Filing time
29 Dec 2023, 16:33:36 UTC
Previous filing
06 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $0 +443,514 $0.000000 443,514 29 Dec 2023 Common Stock 443,514 $1.80 Direct F1
transaction PYXS Stock Option (Right to Buy) Award $0 +110,878 $0.000000 110,878 29 Dec 2023 Common Stock 110,878 $1.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
F2 The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201.